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positioning methods. The doses received by 20%, 40% and 50% 
volume of bladder were compared to those of the original 
treatment plans. 
Results: Based on contours from CBCT images, for bony 
anatomy positioning method the delivered bladder doses 
were on average 591.7 cGy (± 276), 413.6 cGy (± 178), 367.4 
cGy (± 93) lower than the planned dose for D20%, D40%, D50% 
respectively. For fiducial positioning method, they were 
141.2 cGy (± 84), 82.2 cGy (± 61), 67.3 cGy (± 47) lower than 
the planned dose respectively. The dose difference between 
planned and delivered dose shows that the greatest variation 
depending on the bladder filling among the fractions. 
Although, significant differences in bladder volumes and 
subsequent increases in dose were observed in two out of ten 
patients, the bladder doses are still within the acceptance 
criteria. Results indicate a wide range in bladder doses 
throughout treatment, which partly depends on the methods 
used for patient positioning. Of the two patient positioning 
methods evaluated, the least amount of bladder dose 
variability, is seen when target localization was made using 
intraprostatic fiducials. 
Conclusions: Large interfraction variations in bladder filling 
hamper accurate radiotherapy of prostate cancer. Although 
the reproducibility of bladder filling during treatment is low, 
since the estimated mean bladder volume is generally larger 
when compared with the value at the planning CT scan, the 
bladder doses are within the tolerance limits. 
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Purpose/Objective: Late rectal toxicity is one of the most 
important negative consequencies of radiation therapy in 
patients with prostatic carcinoma (CAP). In a previous study 
we observed a significant correlation between proctoscopy 
outcome one year after RT and late rectal toxicity during the 
follow-up. Therefore we proposed early proctoscopy as a 
surrogate end-point for late rectal toxicity. Aim of this study 
was to investigate predictive factors of late rectal toxicity by 
proctoscopy. 
Materials and Methods: The analysis included all patients 
who underwent proctoscopy one year after the end of 
radiation therapy. Proctoscopy was performed by the same 
operators, using Wachter score. The following parameters 
were analyzed as potential predictive factors: RT dose, 
fractionation, pelvic lymph nodes irradiation, previous 
prostatectomy, timing and type of hormone therapy. 
Statistical analysis was performed using the chi-square test 
(univariate analysis) and logistic model (multivariate 
analysis). 
Results: In this analysis 157 patients with non metastatic CAP 
treated with curative and adjuvant RT were included. 
The results are shown in the table below. 
 
Conclusions: In a proctoscopy evaluation of radiation-
induced rectal toxicity only patients who underwent adjuvant 
hormonal therapy based on LH-RH- analogues, showed a 
trend to a higher risk of toxicity. The lack of correlation with 
other clinical parameters can be partially explained by the 
use of SIB-based modulated techniques (IMR-VMAT) in 
patients treated with hypofractionated RT. 
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Purpose/Objective: MR imaging following needle 
implantation in high dose rate brachytherapy (HDR BT) 
provide more anatomical details for improved definition of 
the prostate gland, organs at risk, and needles. The purpose 
of this study was to evaluate the introduction of MRI guided 
HDR BT, including time consumption, dose volume 
parameters, and changes over time.  
Materials and Methods: A team of radiation oncologists, 
physicists, radiologists, and nurses was trained to perform 
MRI guided HDR BT. Between September 2012 and November 
2014, 42 consecutive high risk prostate cancer patients 
received two times HDR BT of each 8.5 Gy after EBRT. Time 
was recorded for initiation of anaesthesia, end of ultrasound 
guided needle implantation, MR scan, and HDR BT delivery. 
We defined implantation time as duration from initiation of 
anaesthesia to end of needle implantation, and total 
procedure time as duration from initiation of anaesthesia to 
end of HDR BT delivery. Dose volume parameters were 
retrieved from the dose planning system. 
Results: Implantation time was reduced from an initial level 
of ~4.5 hours min to ~2.5 hours at ~800 days from 
introduction. Implantation time at the second HDR BT 
procedure was in average 12 min faster than the first. Total 
procedure time was reduced from an initial level of ~10 hours 
min to ~5 hours min at ~800 days from introduction. Total 
procedure time of the second HDR BT was in average 17 min 
faster than the first. Estimated extra time consumption of 
the post implant MRI was median 66 min (range 26-195 min). 
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CTVprostate+3mm D90 was in accordance with institutional 
constraints (95% of prescribed dose) in 74 of 81 procedures. 
Insufficient coverage was caused by suboptimal needle 
implant (5 procedures) and catheter migration (2 
procedures). CTVprostate+3mm D90 was significantly improved 
over time, and tended to be better at the second HDR BT. 
Urethral dose D0.1cc constraints was fulfilled (<=10 Gy) in 65 
of 81 procedures. Rectal dose D2cc constraint was fulfilled 
(<6.4 Gy) in 79 of 81 procedures. Increased CTVprostate+3mm D90 
was not related with increased urethral or rectal dose. 
Conclusions: After introduction of MRI guided HDR BT, 
implant time and total procedure time was reduced to ~2.5 
hours and ~5 hours, respectively. Post implant MRI prolonged 
the HDR BT procedure by an estimated median of 66 min. 
Dose to CTVprostate+3mm mostly fulfilled institutional constraints 
and was improved over time, but not at the expense of an 
increased urethral or rectal dose.  
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Purpose/Objective: The aim of the present prospective study 
is to analyze short and intermediate-term outcomes and 
toxicity after salvage brachytherapy (BT) with I-125 for local 
failure after BT or external beam radiotherapy (EBRT) for 
prostate cancer. 
Materials and Methods: From January 2010 and September 
2014, 24 patients with PSA relapse (Phoenix definition for 
those with previous androgen deprivation (AD) and ASTRO 
definition for the rest), and histological confirmation with 
template-guided biopsy, underwent salvage BT with I-125 at 
least 2 years after the initial treatment (15 BT and 9 EBRT). 
Magnetic resonance imaging (MRI) and/or PET-CT as study of 
distant disease were realized in every case. At relapse, 
average age was 71 years (58-82), median Gleason was 7 and 
PSA pre-salvage BT 5.65 ng/ml (2.81-11.7). Two patients 
were treated with androgen deprivation therapy (ADT) 
previously salvage BT. The median dose to 90% of prostate 
volume was 129.1 Gy (84.18-151.47) with a median seed 
activity of 0.506 mCi (0.319-0.518). Constraint median doses 
for urethra and rectum were 162 Gy and 120 Gy, 
respectively. Every case required post-planning with post 
implant-CT. Post implant-MRI was realized in-patient without 
history of brachytherapy with iodine-125 radiation seeds. 
Toxicities were graded using CTCv4.0. 
Results: With a median follow up of 39 months (2-55): 19 
(79%) patients are free from biochemical failure, 3 patients 
have developed PSA relapse with distant failure evidence, 2 
patients presented PSA relapse within the first 6-12 months 
after salvage brachytherapy. The toxicities found 
corresponding to: one case grade 3 (TURP after acute urine 
retention) and two cases grade 2 (acute rectal mucositis and 
acute cystitis in the same patient). 
Conclusions: Despite of the short follow-up in some patients, 
BT seems to be a safe and effective treatment option for 
salvage treatment, but careful patient selection is essential 
to improve outcomes. 
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Purpose/Objective: Stereotactic Ablative Radiotherapy 
(SABR) is increasing in popularity in several tumour sites 
including prostate cancer. A pilot study of low to 
intermediate risk Prostate cancer patients treated using 
Volumetric Arc Therapy (VMAT) and Flattening Filter Free 
(FFF) beams is ongoing at our institution. Initial toxicity data 
are presented in this report. 
Materials and Methods: Key inclusion criteria in the study 
was patients with low to intermediate risk, localised Prostate 
cancer. Staging was performed using MRI in all patients and a 
bone scan in selected cases. Planning CT and MRI were 
obtained on the same day, with bladder and bowel 
preparation. MRI and CT planning scans were fused and, 
following this, prostate, seminal vesicles and organs at risk 
were outlined by a consultant Clinical Oncologist. VMAT plans 
were produced utilising 10X FFF beams RapidArc 10.028 and 
AAA 10.0.2.28 algorithms. Patients were treated on a Varian 
TrueBeam STx Linear Accelerator at a dose of 35Gy/5 
fractions delivered on alternate days. Cone Beam CT was 
used before each treatment to verify treatment position 
using fiducial marker (gold seed) and soft tissue matching. 
Toxicity was assessed using RTOG toxicity grading prior to 
each fraction of radiotherapy and then at week 4, 10, 18 and 
6 months.  
Results: To date, 22 patients have been enrolled into the 
study. Median age is 70 years, range 52-78yrs. All patients 
have clinical and radiological stage T1-2 disease. Median iPSA 
was 10.65, range 4-29.2 µg/l. 
We have toxicity data on 17 patients who have so far 
completed at least 10 weeks follow up, assessed using RTOG 
acute toxicity scoring. 
 Genitourinary toxicity;  
o 9 patients (53%) had grade 1 symptoms at 
baseline  
o 6 patients (35%) developed grade 2 
toxicity; resolved to grade 1 by week 18 
in all patients (1 not yet reached week 18 
follow-up)  
 
 Gastrointestinal toxicity  
o 2 patients (12%) developed grade 2 
toxicity; both resolved to grade 1, 1 
patient by week 18 and the second 
patient by week 24.  
 
No patient experienced any Grade 3 or 4 toxicity. 
Conclusions: These preliminary data show that treating low 
to intermediate risk prostate cancer patients with SABR using 
VMAT and FFF is safe and deliverable in a busy Tertiary Care 
referral centre with mild, acute GI and GU toxicity. Long 
